Allos Therapeutics (ALTH) Higher Following FDA Panel Recommendation of FOLOTYN
Tweet Send to a Friend
Allos Therapeutics, Inc. (Nasdaq: ALTH) is trading 4% higher in pre-open trading following last night's news that an FDA panel ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
